Fatal haemorrhagic myocarditis secondary to cyclophosphamide therapy.
Haemorrhagic myocarditis is a rare but important complication of cyclophosphamide therapy. Echocardiographic identification of the disorder can be made. We believe that the ultrasound features of this disorder have not been previously reported.
Birchall
I W
IW
Department of Oncologic Imaging, Cross Cancer Institute, Edmonton, Alberta, Canada.
Lalani
Z
Z
Venner
P
P
Hugh
J
J
D000328:Adult; D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000009:adverse effects*; D004452:Echocardiography / Q000379:methods; D017809:Fatal Outcome; D006406:Hematoma / Q000139:chemically induced; D006470:Hemorrhage / Q000139:chemically induced*; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary; D008297:Male; D009205:Myocarditis / Q000139:chemically induced*; D012186:Retroperitoneal Neoplasms / Q000188:drug therapy / Q000556:secondary; D012187:Retroperitoneal Space; D013736:Testicular Neoplasms / Q000188:drug therapy
D018906:Antineoplastic Agents, Alkylating; D003520:Cyclophosphamide